电子圆二色谱（ECD）计算服务 其它资料 蚂蚁淘在线 LabonWeb

technologies products We develop proprietary technology and licensing partnerships to ensure you have access to best-in-class solutions that add value to your own science. regulatory support In close collaboration with you, Lonza Regulatory Affairs provide a CMC dossier suitable to the stage of clinical development of your product manufactured by Lonza. technical support The collective expertise of our multi-disciplinary team in protein expression and production processes can help you get the most from our industry-leading technologies. knowledge center Gather additional industry and technical information from our repository of resources and educational content.Exosomes are small membrane vesicles that are secreted by a multitude of cell types, which play a role in cell to cell communication. They can serve as clinically valuable tools for early diagnosis, prognosis and potentially targeted treatment.From a manufacturing stand-point, the challenge resides not only in the production but also in the characterization. Exosomes have the potential to make cell and gene therapies commercially viable for large populations.We are still at a very early stage and most developers of these innovative technologies are in pre-clinical or early clinical stages, working to demonstrate the efficacy and the potential of exosomes-based therapies.Prime biological cargo deliveryExosomes are produced by all cells. They are a sub-group of extracellular vesicle with a size range typically between 30 and 150 nm, have a Phospholipid Bilayer shell with specific surface markers, and a genetic package containing of RNA, DNA and proteins.Asset 1Some cells can use exosomes to transfer genetic material from one to another. Specifically, an exosome can transfer microRNAs to control the expression of a gene, and messenger RNAs to manufacture proteins. They also transfer proteins themselves, lipids, DNA and others.Exosomes are acting as cargo delivery systems in our body to deliver specific packages with positive or negative messages from one cell to another in a targeted way at distance. Simply put, they are a fresh and well conserved source of biomarkers coming from live cells which reflect those of the parenteral cells.So what stands in the way?Artboard 3 copy 6Aside from decoding the biology and mechanism for therapeutic effect in this novel field, these are some key challenges faced by exosomes-based therapy developers. Those are linked to the very early and pre-clinical stage which most of the exosomes-based therapies are in. There are limited characterization methods available, a need for precise isolation and purification methods and few partners who can provide access to end-to-end GMP manufacturing expertise. Identifying optimal formulation, obtaining starting cell-lines, media, gene editing cargo loading can be a challenge, as well as defining functional assays.No mountain high enoughChoosing the right partner becomes critical in such a pioneering field. By leveraging our knowledge in 2D/3D cell culture and our viral manufacturing expertise, alongside the latest exosome characterization technologies, we can provide a complete path for exosome manufacturing.CharacterizationA complete set of measurement tools to enable both upstream and downstream process development as well as quality control and product characterization Further characterization techniques currently on trial in R D, targeted mid-2020 for GMP use FACS - FLourescence-activated cell sorting qPCR - Real-time quantitative polymerase-chain-reaction ELISA - enzyme-linked immunosorbent assay Tissue acquisition and cell isolation (or exising cell line) Nucleofection / electroporation: Lonza Nucleofector™ and other electroporation methods Lentiviral and AAV transduction methods Large-scale 2D systems: CellSTACK®s and cell factories Large-scale 3D systems: stir tank bioreactor (adherent and aggregate based cultures), Wave Bioreactor™ (suspension based cultures), hollow fiber (Quantum®) Process parameters to achieve final composition of exosome in bulk DS Shipping and storage End-to-end traceability, identification and injection Selection of appropriate buffer and excipients to have optimal formulatuon for improved stability Development services for lyophilization of exosome for 5°C storage Freeze / thaw and agitation study to support handling and transportation Stability studies, manufacturing compatibility, particle assessment ID testing*, light stability Overfills, container closure system selection qualification, container closure integrity in frozen state* Extractables / leachables testing, in-use clinical administration design (pharmacy manual) and testing GMP DP manufacturing QC release and stability studies (including project specific development) and implementation of Pharmacopeia methods Implementation of purity methods from customer for QC release and stability Leveraging 20+ years experience of cell therapy upstream and viral vector downstream, alongside 100+ iPSC, HEK and MSC customer projects 2+ years of exosome manufacturing expertise, including research and development Exosomes are strategic to our business and we are investing in expanding our capabilities in this area Partnership with Exosomics S.p.A. to enable enhanced characterization technologies Extensive bioprocessing and bioreactor experience for a wide range of applications Development of manufacturing processes using various starting cell types including somatic cells, pluripotent and tissue-specific stem cells End-to-end service offering: Phase appropriate assay and process qualification Full characterization Tissue acquisition and cell line development Upstream, downstream, formulation and fill finish Supply chain orchestration system through partnerships Lifecycle regulatory support Thought leadership through global, dedicated exosomes projects and collaborations Open to a variety of collaboration options with exosomes developers Clinical Manufacturing, Commercial Manufacturing, Cell and Gene Manufacturing, Viral Vector Manufacturing Clinical Manufacturing, Commercial Manufacturing, Cell and Gene Manufacturing, Process Development, Analytical Development All trademarks belong to their respective owners and are only being used for informational purposes.

ES色谱柱 在最严苛的条件中也能表现出卓越的峰形 ES Industries | 现货 140 天后结束 梅特勒-托利多 电化学配件 氧化还原电极（ORP电极） 梅特勒-托利多 | 现货 139 天后结束 InertCap 全系列气相色谱柱免费试用 GL Sciences 技尔（上海） | 现货 266 天后结束 GL Scicences固相萃取产品全系列开放免费试用 GL Sciences 技尔（上海） | 现货 257 天后结束 详细信息 外泌体（Exosomes）蛋白提取试剂盒细胞器分离货号规格价格 100T￥1000元 50T￥600元产品概述外泌体蛋白提取 外泌体蛋白提取试剂盒适用于从各种方法得到的外泌体样本中提取总蛋白。 本试剂盒提取的蛋白可用于Western Blotting、蛋白质电泳、免疫沉淀、酶活测定等下游蛋白研究实验。 生化试剂 外泌体（Exosomes）蛋白提取试剂盒由上海联迈生物工程有限公司为您提供，如想了解更多关于ELISA试剂盒 外泌体（Exosomes）蛋白提取试剂盒的报价、规格、厂家等信息，欢迎来电或留言咨询。除供应外泌体（Exosomes）蛋白提取试剂盒外，上海联迈生物工程有限公司还可为您提供： 小鼠脊髓神经元分离培养试剂盒、

业务咨询，请发送邮件到以下邮箱，谢谢合作
Email：info@yinfotek.com

自然界中许多天然化合物分子具有光学手性，正确确定一个有机化合物分子的立体构型，是有机化学工作者尤其是药物研究工作者不可忽视的工作。由于电子圆二色谱（electrostaticcirculardichroism,ECD）对分子基团的空间取向非常敏感，能够提供手性分子的三维结构信息，已成为探索手性分子空间绝对构型的有力工具。

目前，采用理论模拟计算手性分子的电子圆二色谱（ECD），通过你和实验值来确定手性分子绝对构型的方法已被广泛应用于手性化合物分子绝对构型确证研究。根据大量文献报道，时间依赖的密度泛函理论（TDDFT）为目前最为流行的理论方法，多构象玻尔兹曼加权平均方法则是最稳定可靠的模拟方法。

采用ECD计算与实验相结合的方法，能够快速确定手性分子的绝对构型。

完整的ECD计算流程包括：

殷赋科技为广大科研工作者提供了一套完整、高效的ECD计算服务，欢迎垂询！

2021年7月26日外泌体蛋白提取 外泌体蛋白提取试剂盒适用于从各种方法得到的外泌体样本中提取总蛋白。 本试剂盒提取的蛋白可用于Western Blotting、蛋白质电泳、免疫沉淀、酶活测定等下游蛋白研究...

Leverage our knowledge in 2D/3D cell culture and the latest exosome characterization technologies to define your complete path for exosome manufacturing.